Assessment of Transcranial Alternating Current Stimulation's Clinical Efficacy in Treating Cognitive Impairment of Idiopathic Inflammatory Demyelinating Diseases
NCT07087873, Not applicable, Recruiting, Xuanwu Hospital, Beijing
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Assessment of Transcranial Alternating Current Stimulation's Clinical Efficacy in Treating Cognitive Impairment of Idiopathic Inflammatory Demyelinating Diseases | ClinicalTrials.gov |
| NCT number | NCT07087873 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 128 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Xuanwu Hospital, Beijing | ClinicalTrials.gov |
| Conditions | Idiopathic Inflammatory Demyelinating Disorders of the Central Nervous System, MS (Multiple Sclerosis), NMOSD, Acute Disseminated Encephalomyelitis, Transcranial Alternating Current Stimulation | ClinicalTrials.gov |
| Interventions | Neuroelectrical modulation group, Pseudo-neuromodulation group | ClinicalTrials.gov |
| First posted | 2025-07-28 | ClinicalTrials.gov |
| Last updated | 2025-07-28 | ClinicalTrials.gov |
Registered outcomes 9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Expanded Disability Status Scale, EDSS score | At the 5-day point of treatment and 1 month following the end of treatment | 0-10 points, the higher the score, the more serious | ClinicalTrials.gov |
| Primary | Symbol Digit Modalities Test (SDMT) scale | At the 5-day point of treatment and 1 month following the end of treatment | 0-110 points, the higher the score, the better the cognitive function | ClinicalTrials.gov |
| Primary | Scoring results for tasks 1 and 7 in the Alzheimer disease assessment scale-cog(ADAS-cog) | At the 5-day point of treatment and 1 month following the end of treatment | the higher the score, the better the cognitive function | ClinicalTrials.gov |
| Secondary | Mini-mental State Examination（MMSE） | At the 5-day point of treatment and 1 month following the end of treatment | 0-30，the higher the score, the better the cognitive function | ClinicalTrials.gov |
| Secondary | Montreal-Cognitive Assessment（MoCA） | At the 5-day point of treatment and 1 month following the end of treatment | 0-30，the higher the score, the better the cognitive function | ClinicalTrials.gov |
| Secondary | Stroop Color-Word Test score | At the 5-day point of treatment and 1 month following the end of treatment | the higher the score, the better the cognitive function | ClinicalTrials.gov |
| Secondary | Hamilton Depression Scale，HAMD | At the 5-day point of treatment and 1 month following the end of treatment | The higher the score, the worse the depression. | ClinicalTrials.gov |
| Secondary | Hamilton Anxiety Scale，HAMA | At the 5-day point of treatment and 1 month following the end of treatment | The higher the score, the worse the anxiety. | ClinicalTrials.gov |
| Secondary | a subjective questionnaire，adverse effects | Following the first day of treatment，Following the second day of treatment，Following the third day of treatment，Following the fourth day of treatment，Following the fifth day of treatment | The intensity is scored from 0 to 4 | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 2
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Symbol Coding | Primary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)